Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with rBet v1-FV for Birch Pollen Allergy
NCT00266526Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Jul 2003
- Primary completion
- Jul 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rBet v1-FV in birch pollen allergy (2 arms), sponsored by Allergopharma. Primary endpoint: Combined Symptom Medication Score. Started Jul 2003; status: completed.
02
Drugs
rBet v1-FV
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT00266526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266526.